Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7934 results

Sort By:

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Study ID: NCT00539162
Start Date: 2001-07-02
End Date: 2028-11-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

8000

Intervention / Treatment

Questionnaire

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

MeFAMP for Imaging System a Amino Acid Transport in Primary and Metastatic Brain Tumors

Study ID: NCT05676489
Start Date: 2025-12-30
End Date: 2027-08-30
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

28

Intervention / Treatment

[F-18]MeFAMP PET

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Study ID: NCT04879329
Start Date: 2022-05-03
End Date: 2028-06-03
Study Type

Interventional

Study Phase

Phase2

No. of Participants

372

Intervention / Treatment

on Vedotin

pembrolizumab

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Source: clinicaltrials.gov

Share:
Add to list

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Study ID: NCT05794880
Start Date: 2023-05-01
End Date: 2032-05
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Study ID: NCT04827862
Start Date: 2022-07-01
End Date: 2025-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Pembrolizumab

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

Venetoclax Combined with Vyxeos (CPX-351) for Participants with Relapsed or Refractory Acute Leukemia

Study ID: NCT03826992
Start Date: 2018-12-27
End Date: 2028-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

21

Intervention / Treatment

Push

Venetoclax

Sponsor

Children's Hospital Medical Center, Cincinnati

Source: clinicaltrials.gov

Share:
Add to list

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Study ID: NCT03065062
Start Date: 2017-02-28
End Date: 2026-01-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

96

Intervention / Treatment

Palbociclib

Hydropower

Sponsor

Dana-Farber Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Study ID: NCT06568562
Start Date: 2024-12-09
End Date: 2028-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

32

Intervention / Treatment

XL092

Sponsor

University of Utah

Source: clinicaltrials.gov

Share:
Add to list

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Study ID: NCT06859762
Start Date: 2025-07
End Date: 2027-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

220

Intervention / Treatment

YL217 every 3 weeks (Q3W) intravenous (IV) infusion

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

Study ID: NCT04723862
Start Date: 2021-11-12
End Date: 2025-10-01
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

32

Intervention / Treatment

Spironolactone

Placebo

Sponsor

University of Virginia

Source: clinicaltrials.gov

Share:
Add to list